Atazanavir Sulfate, CAS number 229975-97-7, is essential in the management of HIV in affected patients. As an inhibitor of the HIV-1 protease, atazanavir sulfate is often used in combination with other antiretroviral medications to treat HIV-1 infected patients. LGM Pharma is a provider of the API atazanavir sulfate for research and development.
With a trade name Reyataz (Bristol-Myers Squibb), atazanavir sulfate is available in capsule form, in doses of 100, 150, 200 or 300 milligrams. Patients commonly receive one dose daily, alongside additional medications, as well as food. A typical complementary treatment given alongside atazanavir sulfate is ritonavir. Atazanavir is also a stand alone option for those patients who cannot tolerate ritonavir. Also offered as a prophylaxis for possible HIV exposure to healthcare workers, atazanavir sulfate is crucial to the treatment of HIV-1 infections.
Contraindications include hyperbilirubinemia, cardiac abnormalities, rash and dermatological reactions, hyperglycemia, hemophilia and hepatic impairment. Common side effects include headache, dizziness, depression, insomnia, diarrhea, abdominal pain and jaundice. Even with the negative effects possible with treatment for patients using atazanavir sulfate, the positive effects of this drug greatly outweigh the negative effects. Atazanavir sulfate enables patients with HIV to extend their lives and manage their symptoms and disease.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.